Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | COPS5 | Q92905 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18840282 | 0.78 | NOS1 (0.37) | ALDH1A1HPGDNOS1PIK3CGKMT2A | |
| SCHEMBL944021 | 0.76 | NOS1 (0.52) | ALDH1A1HPGDNOS1PIK3CGKMT2A | |
| SCHEMBL2678408 | 0.76 | NOS1 (0.52) | ALDH1A1HPGDNOS1PIK3CGGAA | |
| SCHEMBL19486516 | 0.76 | ALDH1A1 (0.43) | ALDH1A1HPGDNOS1PIK3CGGAA | |
| SCHEMBL19302384 | 0.74 | ALDH1A1 (0.35) | ALDH1A1HPGDNOS1PIK3CGKMT2A | |
| SCHEMBL20877405 | 0.74 | NOS1 (0.34) | ALDH1A1HPGDNOS1PIK3CGKMT2A | |
| SCHEMBL20791827 | 0.74 | ALDH1A1 (0.42) | ALDH1A1HPGDNOS1PIK3CG | |
| SCHEMBL24007297 | 0.74 | NOS1 (0.34) | ALDH1A1HPGDNOS1PIK3CGKMT2A | |
| SCHEMBL77909 | 0.74 | ALDH1A1 (0.42) | ALDH1A1HPGDNOS1PIK3CGKMT2A | |
| SCHEMBL6899340 | 0.73 | KMT2A (0.34) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220143042-A1 | FUSED GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2022-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220143042-A1 | FUSED GLYCOSIDASE INHIBITORS | BACE1, ENGASE, GBA3 | ALDH1A1 628/4885HPGD 2453/4885NOS1 1885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.